vASCULAR AND CARDIAC REMODELLING AND COMbINATION THERAPY OF ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONIC ObSTRUCTIvE PULMONARY DISEASE

Shpagina, L. A.; Шпагин, И. С.; Поспелова, Т И; Герасименко, О Н; Сухатерина, Н А; Аличева, Я. М.

doi:10.15829/1560-4071-2014-1-95-100

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(5)(6)(7) The active involvement of the vascular endothelium in the inflammatory process is recognized in this disease. (8) Metabolic abnormalities like type 2 diabetes, obesity and MetS are common in COPD. (9) Obesity, physical inactivity, cigarette smoking, corticosteroid use, as well as inflammation and hypoxia, are mechanisms responsible for the development of MetS in COPD patients.…”

Section: Introductionmentioning

confidence: 99%

Polymorphisms of Genes Involved in Endothelial Dysfunction in the Yakuts with COPD and Metabolic Syndrome

Borisova¹,

Кылбанова²,

Asekritova³

et al. 2018

IJBM

View full text Add to dashboard Cite

The aim of our research was to study the association of the-675 4G/5G (rs1799889) SNP of the SERPINE1 (PAI-1) gene and the Arg353Gln G>A (rs6046) SNP of the F7 gene with metabolic syndrome (MetS) in the Yakuts with COPD. Methods and Results: A molecular-genetic examination was conducted in 200 COPD patients of Yakut ethnicity. The main group (MG) consisted of 100 COPD patients with MetS, the comparison group (CG) included 100 COPD patients without MetS. The distribution of genotypes of studied SNPs was in Hardy-Weinberg equilibrium in all cases. Studying the SERPINE1-675 4G/5G SNP, we found the prevalence of a 4G allele in MG, compared to CG (OR=1.84, 95% CI 1.23-2.74; χ 2 =9.06, P=0.003). Incidence of the homozygous 4G/4G mutation was rather high in MG, compared to CG (OR=2.35, 95% CI 1.24-4.44; χ 2 =9.31, P=0.002). According to our data, the presence of MetS in Yakut patients with COPD has been associated with the carrier of the 4G/4G genotype. Studying the F7 Arg353Gln SNP, we found the prevalence of an Arg253 allele in both groups (0.72 in MG and 0.71 in CG; χ 2 =0.01, P=0.91). The homozygous Gln353/Gln353 mutant genotype was rare in both groups (0.12 in MG and 0.10 in CG; OR=1.23, 95% CI 0.50-2.99; χ 2 =0.01, P=0.92). In our study, the F7 Arg353Gln SNP was not associated with protection against MetS in COPD patients.

show abstract